- Home
- AFRI vs ABEO Comparison
AFRI vs ABEO Comparison
Compare AFRI & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AFRI | ABEO |
|---|---|---|
| Founded | 1943 | 1974 |
| Country | Gibraltar | United States |
| Employees | 600 | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.1M | 307.5M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | AFRI | ABEO |
|---|---|---|
| Price | $9.97 | $5.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 10.3K | ★ 851.8K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $1,024.31 |
| Revenue Next Year | N/A | $145.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $7.47 | $4.00 |
| 52 Week High | $11.42 | $7.54 |
Technical Indicators
Market Signals| Indicator | AFRI | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 54.74 | 55.78 |
| Support Level | $9.80 | $5.24 |
| Resistance Level | $10.44 | $6.01 |
| Average True Range (ATR) | 0.24 | 0.23 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 45.52 | 68.79 |
Price Performance
Historical ComparisonAbout AFRI Forafric Global PLC
Forafric Global PLC is engaged in the production and sale of wheat flour, semolina, pasta, and couscous products. The company operates through the Soft Wheat, Durum Wheat, and Couscous & Pasta segments. Its main brands include MAYMOUNA and TRIA. It generates the majority of its revenue from the Soft Wheat segment.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.